Zacks Investment Research downgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a buy rating to a hold rating in a report issued on Friday.
According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “
Separately, HC Wainwright initiated coverage on Checkpoint Therapeutics in a research report on Friday, December 8th. They issued a buy rating and a $11.00 price target for the company.
CKPT opened at $4.30 on Friday. The stock has a market capitalization of $137.66 and a P/E ratio of -4.30. Checkpoint Therapeutics has a 12 month low of $3.20 and a 12 month high of $13.00.
Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Friday, March 16th. The company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.01. The company had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.35 million. Checkpoint Therapeutics had a negative return on equity of 102.39% and a negative net margin of 1,316.72%. analysts expect that Checkpoint Therapeutics will post -0.84 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Checkpoint Therapeutics (CKPT) Stock Rating Lowered by Zacks Investment Research” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/09/checkpoint-therapeutics-ckpt-stock-rating-lowered-by-zacks-investment-research.html.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. Its pipeline consists of human, immuno-oncology, and checkpoint inhibitor antibodies that target programmed death-ligand 1; glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX.
Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.